BioCryst Pharmaceuticals has been granted a patent for compounds that inhibit the complement system, potentially treating diseases with abnormal complement system activity. The patent covers methods of administering these compounds for therapeutic purposes. GlobalData’s report on BioCryst Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on BioCryst Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. BioCryst Pharmaceuticals's grant share as of February 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11866418B2) discloses a method for treating diseases or conditions characterized by aberrant complement system activity. The method involves administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt selected from a specific group of compounds. These diseases include paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, organ transplant rejection, myasthenia gravis, and others.
Furthermore, the patent specifies that the compound administered can be in the form of a hydrochloride salt. This method offers a targeted approach to address conditions related to abnormal complement system activity, providing potential treatment options for patients in need. The patent outlines various scenarios and specific compounds within the defined group for treating conditions like paroxysmal nocturnal hemoglobinuria, emphasizing the importance of tailored therapeutic interventions for such diseases.
To know more about GlobalData’s detailed insights on BioCryst Pharmaceuticals, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
